Revvity Inc. reported second-quarter revenue of $720 million, a 4% increase that included 3% organic growth, as stronger software and reagent sales offset softer demand in China-facing diagnostics. Adjusted earnings per share came in at $1.18, while GAAP EPS was $0.46. Net income totaled $53.9 million. Despite topping internal expectations, Revvity’s margin declined, with adjusted operating profit slipping to 26.6% of revenue from 28.8% a year earlier. Management highlighted disciplined cost controls and continued share repurchases alongside an active mergers-and-acquisitions pipeline. The life-science tools company raised its full-year 2025 outlook, projecting revenue of $2.84-$2.88 billion and adjusted EPS of $4.85-$4.95, citing currency benefits and steady mid-single-digit organic growth. Shares were down about 5.7% in pre-market trading following the earnings release.